Yahoo Finance • 15 days ago
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report d... Full story
Yahoo Finance • 24 days ago
Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now. The company currently commands an optimistic outlook, with management remaining confident in achieving key clinical endpoints and biomarker data. This... Full story
Yahoo Finance • 29 days ago
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today a... Full story
Yahoo Finance • last month
The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the... Full story
Yahoo Finance • last month
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story
Yahoo Finance • 2 months ago
Introduction & Market Context Kymera Therapeutics (NASDAQ:KYMR) presented its second quarter 2025 financial results on August 11, 2025, highlighting progress across its immunology pipeline despite a significant revenue decline. The compan... Full story
Yahoo Finance • 2 months ago
Kymera Therapeutics Inc (NASDAQ:KYMR [https://www.chartmill.com/stock/quote/KYMR]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company’s stock saw a pre... Full story
Yahoo Finance • 2 months ago
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD)... Full story
Yahoo Finance • 3 months ago
[Gilead corporate headquarters in Silicon Valley] Sundry Photography * Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process re... Full story
Yahoo Finance • 3 months ago
There’s no doubt about it: the stock market’s strong performance over the past few months is fueling an optimistic mood. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools... Full story
Yahoo Finance • 3 months ago
Investing.com - Brookline Capital Markets has lowered its price target on Kymera Therapeutics (NASDAQ:KYMR) to $65.00 from $70.00 while maintaining a Buy rating on the stock. The new target represents a significant upside from the current... Full story
Yahoo Finance • 3 months ago
Investing.com - Morgan Stanley initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Overweight rating and a $70.00 price target, highlighting the company’s protein degradation and drug discovery expertise. The stock has shown st... Full story
Yahoo Finance • 3 months ago
This article summarizes the top insider buys and sells reported on Tuesday, July 1, 2025, for US stocks. Top Insider Buys: Kymera Therapeutics Inc (NASDAQ:KYMR): A group of directors, including Mark N Lampert, collectively purchased $13... Full story
Yahoo Finance • 3 months ago
This article summarizes the most significant insider buys and sells reported for US stocks on Monday, June 30, 2025. Top Insider Buys: • Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw substantial insider buying from Baker Bros. Advisors and... Full story
Yahoo Finance • 3 months ago
Baker Bros. Advisors and related entities reported purchasing shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 30, 2025. The biotechnology company, currently valued at $2.89 billion, has shown strong momentum with a 41% return ove... Full story
Yahoo Finance • 3 months ago
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KY... Full story
Yahoo Finance • 3 months ago
Investing.com - BofA Securities raised its price target on Kymera Therapeutics (NASDAQ:KYMR) to $54.00 from $51.00 on Thursday, while maintaining a Buy rating on the stock following several pipeline developments. The stock, currently tradi... Full story
Yahoo Finance • 3 months ago
Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. The firm reiterated its Outperform rating while lowering... Full story
Yahoo Finance • 3 months ago
* Kymera Therapeutics (NASDAQ:KYMR [https://seekingalpha.com/symbol/KYMR]) priced [https://seekingalpha.com/pr/20150243-kymera-therapeutics-announces-pricing-of-250-million-public-offering] its underwritten public offering of $250.8M sha... Full story
Yahoo Finance • 3 months ago
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story